Tag Archives: Genzyme

Biotech Could Miss a Multi-Billion Dollar Opportunity in Rare Disease


Drug development is expensive.  Drug development is risky.  Drug development takes a long time. The key to changing this is leveraging the fact that no one is more motivated to eliminate rare disease than those who are directly affected by it. I know this because, as the founder of Give RARE, I have talked to parents of children with Tay Sachs disease who know their children will die within a few years unless something changes.  Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Cohen, Boyer & Tibbetts?

SBIR Reauthorization Moves Forward

Ask any biotech professional about Stanley Cohen and Herbert Boyer and they will tell you about their incredible contributions to modern biotechnology. But what about Roland Tibbetts? My guess is there are more than a few quizzical looks out there. So who is Roland Tibbetts? In many ways, Roland Tibbetts did for the commercialization of biotechnology, what Cohen and Boyer did for the science. He is the creator of the Small Business Innovation Research (SBIR) Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

33713_Viehbacher_100x100 copy

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,